Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma

被引：3
作者：
Davidson, Michael [1 ]
Smyth, Elizabeth C. [1 ]
Cunningham, David [1 ]
机构：
[1] Royal Marsden Hosp NHS Fdn Trust, Dept Gastrointestinal Canc Res, London, England
来源：
ONCOTARGETS AND THERAPY | 2016年 / 9卷
关键词：
advanced gastric cancer; ramucirumab; paclitaxel; angiogenesis inhibitors; RANDOMIZED PHASE-III; ENDOTHELIAL GROWTH-FACTOR; DOUBLE-BLIND; OPEN-LABEL; 1ST-LINE THERAPY; PLUS PACLITAXEL; COMPARING IRINOTECAN; 2ND-LINE TREATMENT; SUPPORTIVE CARE; CANCER;
D O I：
10.2147/OTT.S84153
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Cancers of the stomach and gastro-esophageal junction represent a significant challenge in oncology. Despite some recent advances in genetic categorization and the development of novel agents, outcomes remain poor. The vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab is the first targeted therapy to improve survival in a molecularly unselected population, and represents a valuable new treatment option. This review describes the current treatment landscape for advanced disease, evaluates existing and ongoing research into ramucirumab, and discusses its current and potential future therapeutic role.
引用
收藏
页码：4539 / 4548
页数：10
相关论文
共 51 条
[1]  
[Anonymous], J CLIN ONCOL S
[2]  
[Anonymous], 2015, J CLIN ONCOL S
[3]  
[Anonymous], GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012
[4]  
[Anonymous], RAM TREAT ADV GASTR
[5]  
Bang YJ, 2010, LANCET, V376, P1302
[6]   Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer [J].
Bang, Yung-Jue ;
Im, Seock-Ah ;
Lee, Keun-Wook ;
Cho, Jae Yong ;
Song, Eun-Kee ;
Lee, Kyung Hee ;
Kim, Yeul Hong ;
Park, Joon Oh ;
Chun, Hoo Geun ;
Zang, Dae Young ;
Fielding, Anitra ;
Rowbottom, Jacqui ;
Hodgson, Darren ;
O'Connor, Mark J. ;
Yin, Xiaolu ;
Kim, Woo Ho .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (33) :3858-+
[7]   Comprehensive molecular characterization of gastric adenocarcinoma [J].
Bass, Adam J. ;
Thorsson, Vesteinn ;
Shmulevich, Ilya ;
Reynolds, Sheila M. ;
Miller, Michael ;
Bernard, Brady ;
Hinoue, Toshinori ;
Laird, Peter W. ;
Curtis, Christina ;
Shen, Hui ;
Weisenberger, Daniel J. ;
Schultz, Nikolaus ;
Shen, Ronglai ;
Weinhold, Nils ;
Keiser, David P. ;
Bowlby, Reanne ;
Sipahimalani, Payal ;
Cherniack, Andrew D. ;
Getz, Gad ;
Liu, Yingchun ;
Noble, Michael S. ;
Pedamallu, Chandra ;
Sougnez, Carrie ;
Taylor-Weiner, Amaro ;
Akbani, Rehan ;
Lee, Ju-Seog ;
Liu, Wenbin ;
Mills, Gordon B. ;
Yang, Da ;
Zhang, Wei ;
Pantazi, Angeliki ;
Parfenov, Michael ;
Gulley, Margaret ;
Piazuelo, M. Blanca ;
Schneider, Barbara G. ;
Kim, Jihun ;
Boussioutas, Alex ;
Sheth, Margi ;
Demchok, John A. ;
Rabkin, Charles S. ;
Willis, Joseph E. ;
Ng, Sam ;
Garman, Katherine ;
Beer, David G. ;
Pennathur, Arjun ;
Raphael, Benjamin J. ;
Wu, Hsin-Ta ;
Odze, Robert ;
Kim, Hark K. ;
Bowen, Jay .
NATURE, 2014, 513 (7517) :202-209
[8]   Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [J].
Bennouna, Jaafar ;
Sastre, Javier ;
Arnold, Dirk ;
Osterlund, Pia ;
Greil, Richard ;
Van Cutsem, Eric ;
von Moos, Roger ;
Maria Vieitez, Jose ;
Bouche, Olivier ;
Borg, Christophe ;
Steffens, Claus-Christoph ;
Alonso-Orduna, Vicente ;
Schlichting, Christoph ;
Reyes-Rivera, Irmarie ;
Bendahmane, Belguendouz ;
Andre, Thierry ;
Kubicka, Stefan .
LANCET ONCOLOGY, 2013, 14 (01) :29-37
[9]   The pharmacological bases of the antiangiogenic activity of paclitaxel [J].
Bocci, Guido ;
Di Paolo, Antonello ;
Danesi, Romano .
ANGIOGENESIS, 2013, 16 (03) :481-492
[10]   VEGFA and tumour angiogenesis [J].
Claesson-Welsh, L. ;
Welsh, M. .
JOURNAL OF INTERNAL MEDICINE, 2013, 273 (02) :114-127
123456